Arcus Biosciences, Inc. (RCUS)
Company Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy.
The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease.
It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer.
The company was incorporated in 2015 and is headquartered in Hayward, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Mar 15, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 366 |
| CEO | Dr. Terry J. Rosen Ph.D. |
Contact Details
Address:
3928 Point Eden Way Hayward, California 94545 United States | |
| Phone | (510) 694-6200 |
| Website | arcusbio.com |
Stock Details
| Ticker Symbol | RCUS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001724521 |
| CUSIP Number | 03969F109 |
| ISIN Number | US03969F1093 |
| Employer ID | 47-3898435 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Terry J. Rosen Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Juan Carlos Jaen Ph.D. | Co-Founder, President and Director |
| Robert C. Goeltz II | Principal Financial and Accounting Officer and Chief Financial Officer |
| Jennifer A. Jarrett M.B.A. | Chief Operating Officer and Director |
| Carolyn C. Tang J.D. | General Counsel and Corporate Secretary |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Stephen Young Ph.D. | Senior Vice President of Technology and Quantitative Biology |
| Dr. Jonathan Yingling Ph.D. | Chief Scientific Officer |
| Katherine Bock | Vice President of Investor Relations and Corporate Strategy |
| Holli Kolkey | Vice President of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 10, 2023 | 8-K | Current Report |
| Feb 28, 2023 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 28, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2023 | 10-K | Annual Report |
| Feb 28, 2023 | 8-K | Current Report |
| Feb 14, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 10, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 26, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |